Neurogene Secures FDA Breakthrough Therapy Designation for NGN-401 in Rett Syndrome
Friday, February 27, 2026
Neurogene has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NGN-401, its investigational gene therapy for Rett syndrome.
Rett syndrome is a rare genetic neurological disorder that mainly affects girls. It is usually caused by mutations in the MECP2 gene, which plays an important role in brain development and function. Children with Rett syndrome often develop normally during the first 6 to 18 months of life. This is followed by a period of regression, where they lose previously acquired skills such as speech and purposeful hand movements.
NGN-401 is designed to deliver the full-length human MECP2 gene using the company’s proprietary EXACT™ transgene regulation technology. This approach aims to provide controlled and consistent MeCP2 protein expression at the cellular level. The therapy is administered through intracerebroventricular delivery to enable broad distribution throughout the brain and nervous system, based on non-clinical biodistribution findings.
The therapy is currently in late-stage clinical development and is being evaluated as a potential one-time treatment for the rare neurological disorder.
The designation follows the FDA’s review of interim efficacy and safety data from the ongoing Phase 1/2 trial, with a data cut-off of 30 October 2025. The review included patient-level data and supporting video documentation. The results showed clinically meaningful and durable improvements across multiple areas of Rett syndrome, along with continued skill development over time.
The treatment is currently being studied in the Embolden™ registrational clinical trial, with dosing expected to be completed in the second quarter of 2026.
Breakthrough Therapy designation is intended to speed up the development and regulatory review of medicines for serious conditions where early clinical evidence indicates potential substantial improvement over existing treatments. The designation allows for closer interaction with the FDA, eligibility for Priority Review and the option for rolling submission of a Biologics License Application.
Interim findings from the Phase 1/2 study indicate that NGN-401 at the 1E15 vg dose has been generally well tolerated, with participants demonstrating sustained and multi-domain functional improvements. The programme continues to progress as a potential treatment option for individuals living with Rett syndrome.
In Europe, NGN-401 has been granted Advanced Therapy Medicinal Product, Orphan and Priority Medicines designations by the European Medicines Agency, and it has also received Innovative Licensing and Application Pathway designation from the United Kingdom Medicines and Healthcare products Regulatory Agency.
Source: neurogene.com
